{"disease":{"id":"refractory-thyroid-gland-hurthle-cell-carcinoma","name":"refractory thyroid gland hurthle cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01208051","title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05410821","title":"Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}